In vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies

References

• Baranczewski P, Stanczak A, Sundberg K, et al. (2006). Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 58:453–72
   PubMed Web of Science ®Google Scholar
• Bhatta RS, Kumar D, Chhonker YS, et al. (2010a). Bioanalytical method development and validation of novel antithrombotic agent S002-333 by LC-MS/MS and its application to pharmacokinetic studies. Biomed Chromatogr 24:1234–9
   PubMed Web of Science ®Google Scholar
• Bhatta RS, Kumar D, Chhonker YS, et al. (2010b). Bioanalytical method development and validation for simultaneous estimation of (R)- and (S)-isomers of S002-333: a potent novel anti-thrombotic agent using LC–MS/MS. Med Chem Res 20:1581–8
   Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, et al. (2003). The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–32
   PubMed Web of Science ®Google Scholar
• Bort R, Mace K, Boobis A, et al. (1999). Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 58:787–96
   PubMed Web of Science ®Google Scholar
• Chang M, Dahl ML, Tybring G, et al. (1995). Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358–63
   PubMedGoogle Scholar
• Crespi CL, Miller VP. (1999). The use of heterologously expressed drug metabolizing enzymes – state of the art and prospects for the future. Pharmacol Ther 84:121–31
   PubMed Web of Science ®Google Scholar
• Farndale RW, Sixma JJ, Barnes MJ, de Groot PG. (2004). The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2:561–73
   PubMed Web of Science ®Google Scholar
• Gaur S, Fatima Z, Dixit A, et al. (2006). 2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9h-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents. Patent No. WO/2006/070385; International Application No. PCT/IN/2004/000417
   Google Scholar
• Gelboin HV, Krausz KW, Gonzalez FJ, Yang TJ. (1999). Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery. Trends Pharmacol Sci 20:432–8
   PubMed Web of Science ®Google Scholar
• Gorman GS, Coward L, Kerstner-Wood C, et al. (2007). In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab Dispos 35:1157–64
   PubMed Web of Science ®Google Scholar
• Greiner B, Rommelspacher H. (1984). Two metabolic pathways of tetrahydronorharmane (tetrahydro-beta-carboline) in rats. Naunyn Schmiedebergs Arch Pharmacol 325:349–55
   PubMed Web of Science ®Google Scholar
• Ha-Duong NT, Dijols S, Macherey AC, et al. (2001). Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40:12112–22
   PubMed Web of Science ®Google Scholar
• Harper TW, Brassil PJ. (2008). Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS J 10:200–7
   PubMed Web of Science ®Google Scholar
• Herraiz T, Guillen H, Aran VJ. (2008). Oxidative metabolism of the bioactive and naturally occurring beta-carboline alkaloids, norharman and harman, by human cytochrome P450 enzymes. Chem Res Toxicol 21:2172–80
   PubMed Web of Science ®Google Scholar
• Hesse LM, Venkatakrishnan K, Court MH, et al. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176–83
   PubMed Web of Science ®Google Scholar
• Imai Y. (1981). The roles of cytochrome b5 in reconstituted monooxygenase systems containing various forms of hepatic microsomal cytochrome P-450. J Biochem 89:351–62
   PubMed Web of Science ®Google Scholar
• Jackson SP, Nesbitt WS, Kulkarni S. (2003). Signaling events underlying thrombus formation. J Thromb Haemost 1:1602–12
   PubMed Web of Science ®Google Scholar
• Kahn ML. (2004). Platelet-collagen responses: molecular basis and therapeutic promise. Semin Thromb Hemost 30:419–25
   PubMed Web of Science ®Google Scholar
• Ko JW, Desta Z, Flockhart DA. (1998). Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab Dispos 26:775–8
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–15
   PubMed Web of Science ®Google Scholar
• Korzhukova PI. (1976). [Prevention of postresection disorders in patients with peptic ulcer]. Ter Arkh 48:77–81
   PubMed Web of Science ®Google Scholar
• Lu AY, Wang RW, Lin JH. (2003). Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 31:345–50
   PubMed Web of Science ®Google Scholar
• Ludwig E, Schmid J, Beschke K, Ebner T. (1999). Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Therapeutics 290:1–8
   PubMed Web of Science ®Google Scholar
• Masubuchi Y, Ose A, Horie T. (2002). Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metab Dispos 30:1143–8
   PubMed Web of Science ®Google Scholar
• Morrison R, Boyd R. (2002). Organic chemistry. New Delhi, India: Prentice-Hall Publisher
   Google Scholar
• Nakajima M, Nakamura S, Tokudome S, et al. (1999). Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 27:1381–91
   PubMed Web of Science ®Google Scholar
• Newton DJ, Wang RW, Lu AY. (1995). Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154–8
   PubMed Web of Science ®Google Scholar
• Nishiya Y, Hagihara K, Ito T, et al. (2009). Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. Drug Metab Dispos 37:589–93
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Maenpaa J, Taavitsainen P, et al. (1998). Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28:1203–53
   PubMed Web of Science ®Google Scholar
• Preskorn SH. (1997). Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 32:1–21
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. (1999). Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465–80
   PubMed Web of Science ®Google Scholar
• Saelman EU, Horton LF, Barnes MJ, et al. (1993). Platelet adhesion to cyanogen-bromide fragments of collagen alpha 1(I) under flow conditions. Blood 82:3029–33
   PubMed Web of Science ®Google Scholar
• Sarratt KL, Chen H, Zutter MM, et al. (2005). GPVI and alpha2beta1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow. Blood 106:1268–77
   PubMed Web of Science ®Google Scholar
• Soars MG, Gelboin HV, Krausz KW, Riley RJ. (2003). A comparison of zrelative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. Br J Clin Pharmacol 55:175–81
   PubMed Web of Science ®Google Scholar
• Stringer RA, Strain-Damerell C, Nicklin P, Houston JB. (2009). Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos 37:1025–34
   PubMed Web of Science ®Google Scholar
• Surin WR, Barthwal MK, Dikshit M. (2008). Platelet collagen receptors, signaling and antagonism: emerging approaches for the prevention of intravascular thrombosis. Thromb Res 122:786–803
   PubMed Web of Science ®Google Scholar
• Takahashi H, Echizen H. (2001). Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 40:587–603
   PubMed Web of Science ®Google Scholar
• Uttamsingh V, Lu C, Miwa G, Gan LS. (2005). Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 33:1723–8
   PubMed Web of Science ®Google Scholar
• Vanhoorelbeke K, Ulrichts H, Schoolmeester A, Deckmyn H. (2003). Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs. Curr Drug Targets Cardiovasc Haematol Disord 3:125–40
   PubMedGoogle Scholar
• Venkatakrishnan K, Schmider J, Harmatz JS, et al. (2001). Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol 41:1043–54
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Court MH, et al. (2000). Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493–504
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. (1998). Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. J Pharm Sci 87:845–53
   PubMed Web of Science ®Google Scholar
• Watkins PB, Murray SA, Thomas PE, Wrighton SA. (1990). Distribution of cytochromes P-450, cytochrome b5, and NADPH-cytochrome P-450 reductase in an entire human liver. Biochem Pharmacol 39:471–6
   PubMed Web of Science ®Google Scholar
• White RH. (2003). The epidemiology of venous thromboembolism. Circulation 107:I4–8
   PubMed Web of Science ®Google Scholar
• Yanni SB, Annaert PP, Augustijns P, et al. (2008). Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos 36:1119–25
   PubMed Web of Science ®Google Scholar
• Yu AM, Idle JR, Krausz KW, et al. (2003). Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Therapeut 305:315–22
   PubMed Web of Science ®Google Scholar